Related Experiment Video
Updated: Mar 3, 2026
11:02
Methods for Experimental Manipulations after Optic Nerve Transection in the Mammalian CNS
Published on: May 12, 2011
14.1K
A Novel Neuroprotective Small Molecule for Glial Cell Derived Neurotrophic Factor Induction and Photoreceptor Rescue
Petr Baranov1, Hong Lin2, Kathryn McCabe2
11 The Schepens Eye Research Institute , Massachusetts Eye and Ear, an affiliate of Harvard Medical School, Boston, Massachusetts.
Summary
A novel small molecule, GSK812, effectively induces glial cell derived neurotrophic factor (GDNF) in the retina. This molecule rescues photoreceptors in models of retinal degeneration, offering a potential treatment for conditions like retinitis pigmentosa.
Area of Science:
- Ophthalmology
- Neuroscience
- Pharmacology
Background:
- Degenerative retinal diseases cause irreversible photoreceptor loss.
- Glial cell derived neurotrophic factor (GDNF) shows potential for rescuing retinal neurons.
- Small molecules can be used to induce GDNF in the retina.
Purpose of the Study:
- To investigate the novel small molecule GSK812's ability to induce GDNF.
- To evaluate GSK812's efficacy in rescuing photoreceptors in vitro and in vivo.
- To assess GSK812 as a potential therapeutic agent for retinal degeneration.
Main Methods:
- GDNF induction was assessed in human retinal cells and mouse eyecups.
- GSK812 was administered via intravitreal injection in a sustained-release formulation.
- Photoreceptor rescue was evaluated in rhodopsin knockout mice and Royal College of Surgeon (RCS) rats.
Main Results:
- GSK812 sustained release provided drug presence in the eye for 2 weeks.
- GSK812 significantly upregulated GDNF mRNA and protein levels in mice.
- GSK812 treatment preserved photoreceptors and outer segments in models of retinal degeneration, with functional preservation in RCS rats.
Conclusions:
- GSK812 is a potent neuroprotectant capable of inducing GDNF in retinal tissues.
- GSK812 demonstrates significant potential for photoreceptor rescue in models of retinal degeneration.
- This study highlights GSK812 as a promising therapeutic candidate for treating degenerative retinal diseases.
